Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Questiomycin B. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.75 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Questiomycin B SCHEMBL11556069 | 1.00 | ALOX15 (0.75) | ALOX15TSHRCA12CA2CA1 | |
| Questiomycin B SCHEMBL1115427 | 1.00 | ALOX15 (0.75) | ALOX15TSHRCA12CA2CA1 | |
| Questiomycin B SCHEMBL28133000 | 0.98 | ALOX15 (0.71) | ALOX15TSHRCA12CA2CA1 | |
| Questiomycin B SCHEMBL4725309 | 0.98 | ALOX15 (0.71) | ALOX15TSHRCA12CA2CA1 | |
| Questiomycin B SCHEMBL11685448 | 0.92 | ALOX15 (0.79) | ALOX15TSHRCA12CA2CA1 | |
| Questiomycin B SCHEMBL29430322 | 0.87 | — | — | |
| Questiomycin B SCHEMBL24436 | 0.87 | — | — | |
| Questiomycin B SCHEMBL3999786 | 0.87 | ALOX15 (1.00) | ALOX15TSHRCA12CA2CA1 | |
| Questiomycin B SCHEMBL31518349 | 0.86 | ALOX15 (0.68) | ALOX15TSHRCA12CA2CA1 | |
| Questiomycin B SCHEMBL1823522 | 0.84 | ALOX15 (0.83) | ALOX15TSHRCA12CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250336540-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-30 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| EP-4515242-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN Pharmaceutica NV (BE) | 2025-03-05 | — | — | EP | claimed |
| WO-2023209218-A1 | METABOLITE PREDICTORS FOR LUNG CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-02 | — | — | WO | claimed |
| US-20220175851-A1 | COMPOSITIONS, METHODS FOR REGULATING UTERINE, PLACENTAL GROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-09 | — | — | US | claimed |
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-11-18 | — | — | US | claimed |
| EP-3852759-A2 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | Yeda Research and Development Co. Ltd (IL) | 2021-07-28 | — | — | EP | claimed |
| CN-113038951-A | Method of treating amyotrophic lateral sclerosis | 耶达研究及发展有限公司 | 2021-06-25 | — | — | CN | claimed |
| WO-2020186161-A2 | COMPOSITIONS AND METHODS FOR REGULATING UTERINE AND PLACENTAL GROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | WO | claimed |
| WO-2020058979-A2 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-03-26 | — | — | WO | claimed |
| US-10548824-B2 | Oxidative hair dying and conditioning composition and method for base breaking hair with an oxidative hair dye | NUMBER THREE INC (JP) | 2020-02-04 | — | — | US | claimed |
| CN-109498484-A | A kind of permanent bubble and its hair colouring methods of having hair dyed | 拉芳家化股份有限公司 | 2019-03-22 | — | — | CN | claimed |
| CN-104127332-B | Composition for oxidative dyeing containing natural materials | 株式会社太平洋 | 2017-04-12 | — | — | CN | claimed |
| CN-103517703-B | Stain and application thereof | 天野酶制品株式会社 | 2016-11-09 | — | — | CN | claimed |
| EP-2361604-B1 | Powder hair dye composition based on sodium percarbonate and storage package therefor | HOYU KK (JP) | 2014-08-27 | — | — | EP | claimed |
| EP-2361604-A1 | Powder hair dye composition based on sodium percarbonate and package therefor | Hoyu Co., Ltd. (JP) | 2011-08-31 | — | — | EP | claimed |
| US-20110203604-A1 | POWDER HAIR DYE COMPOSITION, USE THEREOF AND STORAGE PACKAGE THEREFOR | HOYU CO., LTD. GENERAL RESEARCH INSTITUTE (JP) | 2011-08-25 | — | — | US | claimed |
| WO-2007056569-A2 | LIGHT RESPONSIVE SELF-TANNING PRODUCTS AND METHODS FOR USE | SCALES-MEDEIROS VIRGINIA (US) | 2007-05-18 | — | — | WO | claimed |
| US-6702863-B1 | SINGLE PACKAGE AEROSOL CONPRISED OF 5,6-DIHYDROXYINDOLINE, LACCASE, WATER AND PROPELLANT; NONIRRITATING; STORAGE STABLE | LION CORPORATION (JP) | 2004-03-09 | — | — | US | claimed |
| CN-1116089-A | Natural tea black hair dying agent and making method thereof | HE WEIHUA (CN) | 1996-02-07 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, OAT | ALOX15 383/4885TSHR 4408/4885CA12 2258/4885 |
| US-20220175851-A1 | COMPOSITIONS, METHODS FOR REGULATING UTERINE, PLACENTAL GROWTH | PGF, FGR, VEGFA | ALOX15 1468/4885TSHR 1479/4885CA12 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.